UBS Group
KALV

UBS Group’s KalVista Pharmaceuticals KALV Stock Holding History

UBS Group’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.4M Buy
515,650
+143,657
+39% +$2.32M ﹤0.01% 3300
2025
Q4 		$6.01M Sell
371,993
-82,155
-18% -$1.09M ﹤0.01% 3836
2025
Q3 		$5.53M Buy
454,148
+181,287
+66% +$2.5M ﹤0.01% 3931
2025
Q2 		$3.08M Sell
272,861
-234,842
-46% -$2.87M ﹤0.01% 4364
2025
Q1 		$5.86M Buy
507,703
+133,072
+36% +$1.36M ﹤0.01% 3623
2024
Q4 		$3.17M Buy
374,631
+331,202
+763% +$3.43M ﹤0.01% 4270
2024
Q3 		$503K Buy
43,429
+30,023
+224% +$378K ﹤0.01% 5219
2024
Q2 		$158K Sell
13,406
-15,111
-53% -$176K ﹤0.01% 5828
2024
Q1 		$338K Buy
28,517
+1,413
+5% +$18.8K ﹤0.01% 5489
2023
Q4 		$332K Buy
27,104
+4,838
+22% +$44K ﹤0.01% 5424
2023
Q3 		$214K Buy
22,266
+6,397
+40% +$65.4K ﹤0.01% 5323
2023
Q2 		$143K Buy
15,869
+9,123
+135% +$84.1K ﹤0.01% 5726
2023
Q1 		$53K Sell
6,746
-2,888
-30% -$21.6K ﹤0.01% 6410
2022
Q4 		$65.1K Buy
9,634
+8,402
+682% +$45K ﹤0.01% 6517
2022
Q3 		$18K Buy
1,232
+168
+16% +$2.35K ﹤0.01% 7525
2022
Q2 		$10K Sell
1,064
-41,929
-98% -$463K ﹤0.01% 7967
2022
Q1 		$634K Sell
42,993
-10,570
-20% -$152K ﹤0.01% 4507
2021
Q4 		$708K Buy
53,563
+20,335
+61% +$324K ﹤0.01% 4699
2021
Q3 		$580K Buy
33,228
+28,906
+669% +$586K ﹤0.01% 4630
2021
Q2 		$104K Sell
4,322
-6,454
-60% -$169K ﹤0.01% 5849
2021
Q1 		$277K Buy
10,776
+9,007
+509% +$237K ﹤0.01% 5261
2020
Q4 		$34K Buy
1,769
+1,011
+133% +$17.3K ﹤0.01% 6529
2020
Q3 		$10K Sell
758
-3,557
-82% -$44.5K ﹤0.01% 6850
2020
Q2 		$52K Sell
4,315
-3,196
-43% -$34K ﹤0.01% 5819
2020
Q1 		$57K Sell
7,511
-9,882
-57% -$133K ﹤0.01% 5724
2019
Q4 		$310K Buy
17,393
+6,682
+62% +$87.2K ﹤0.01% 5257
2019
Q3 		$124K Buy
10,711
+8,605
+409% +$139K ﹤0.01% 5625
2019
Q2 		$47K Buy
2,106
+1,621
+334% +$38K ﹤0.01% 5980
2019
Q1 		$14K Buy
+485
New +$10.5K ﹤0.01% 6586
2018
Q4 		– Sell
-660
Closed -$14K – 8164
2018
Q3 		$14K Sell
660
-2,454
-79% -$33.2K ﹤0.01% 7000
2018
Q2 		$25K Buy
3,114
+2,969
+2,048% +$26.2K ﹤0.01% 6536
2018
Q1 		$1K Sell
145
-1,446
-91% -$15.1K ﹤0.01% 7640
2017
Q4 		$16K Buy
+1,591
New +$16.6K ﹤0.01% 6729
2017
Q3 		– Sell
-1,506
Closed -$11K – 7860
2017
Q2 		$11K Sell
1,506
-801
-35% -$5.89K ﹤0.01% 6714
2017
Q1 		$18K Buy
2,307
+1,398
+154% +$10.5K ﹤0.01% 6206
2016
Q4 		$6K Sell
909
-285
-24% -$2.1K ﹤0.01% 7156
2016
Q3 		$8K Sell
1,194
-388
-25% -$2.92K ﹤0.01% 6909
2016
Q2 		$15K Buy
+1,582
New +$18.3K ﹤0.01% 6511
2016
Q1 		– Sell
-53
Closed -$3K – 7904
2015
Q4 		$3K Sell
53
-269
-84% -$14.1K ﹤0.01% 7882
2015
Q3 		$16K Buy
+322
New +$27.4K ﹤0.01% 6904

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group's KALV Position: Q1 2026 in Review

UBS Group increased its KalVista Pharmaceuticals (KALV) stake by 39% in Q1 2026, buying an estimated $2.32M and bringing the position to 515,650 shares worth $10.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3300.

UBS Group first reported a position in KALV in Q3 2015 and has held it in 40 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • UBS Group held 515,650 shares of KalVista Pharmaceuticals worth $10.4M as of Q1 2026.
  • UBS Group bought 143,657 KalVista Pharmaceuticals shares in Q1 2026, an estimated $2.32M.
  • KalVista Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3300 holding.
  • UBS Group first reported a position in KalVista Pharmaceuticals in Q3 2015 and has held it in 40 quarters since.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.